Patents Assigned to Alkermes
  • Patent number: 9498474
    Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: November 22, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Patent number: 9428563
    Abstract: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: August 30, 2016
    Assignee: Alkermes, Inc.
    Inventor: Juan Alvarez
  • Patent number: 9415045
    Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: August 16, 2016
    Assignee: Alkermes, Inc.
    Inventors: Laura Cook Blumberg, Derrick Arnelle
  • Publication number: 20160228555
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Publication number: 20160228554
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 11, 2016
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Patent number: 9365580
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 14, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Patent number: 9359415
    Abstract: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: June 7, 2016
    Assignee: Alkermes, Inc.
    Inventors: Juan Alvarez, Jean Chamoun
  • Patent number: 9345665
    Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: May 24, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
  • Patent number: 9296801
    Abstract: The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: March 29, 2016
    Assignee: Alkermes, Inc.
    Inventors: Juan Alvarez, Leslie A. McSweeney
  • Patent number: 9238076
    Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: January 19, 2016
    Assignees: Alkermes Pharma Ireland Limited, Amylin Pharmaceuticals, LLC
    Inventors: Steven G. Wright, Troy Christensen, Thean Yeoh, Michael E. Rickey, Joyce M. Hotz, Rajesh Kumar, Mark Fineman, Christine Smith, John Ong, David M. Lokensgard, Henry R. Costantino
  • Patent number: 9221830
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: December 29, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Patent number: 9211293
    Abstract: The invention relates a composition comprising an opioid agonist and Compound-1:
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: December 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Elliot Ehrich
  • Publication number: 20150320682
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: May 15, 2015
    Publication date: November 12, 2015
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Douglas Hovey, John Pruitt, Tuula Ryde
  • Patent number: 9156897
    Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: October 13, 2015
    Assignee: Alkermes, Inc.
    Inventors: Juan Alvarez, Jean Chamoun, Heather C. Losey
  • Patent number: 9132231
    Abstract: A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to undergo incremental advancement. The device may also be provided with manual control for delivering a bolus dose of drug when necessary.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: September 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Joseph Gross, Izrail Tsals, Gilad Lavi, Gil Yigal, Ehoud Carmel
  • Patent number: 9132096
    Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: September 15, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell
  • Patent number: 9126977
    Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: September 8, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Daniel Deaver, Mark Todtenkopf
  • Patent number: 9126936
    Abstract: The invention provides a method for the synthesis of dehydrogenated lactam drugs of Formula I:
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: September 8, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
  • Patent number: 9119848
    Abstract: The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: September 1, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Bernard Silverman, Fen-Ni Fu, Chengyun Guo
  • Patent number: 9107911
    Abstract: The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: August 18, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Laura Cook Blumberg, Örn Almarsson